Compare Ares Capital Corporation (ARCC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs Revvity Inc — how do they compare? Ares Capital Corporation trades at $19.85 (market cap $14.34B), while Revvity Inc trades at $116.17 (market cap $12.91B). The key difference: Ares Capital Corporation and Revvity Inc are close in size by market cap, and Ares Capital Corporation pays the higher dividend (9.61%). Which is the better fit depends on your goals.
| ARCC | RVTY | |
|---|---|---|
Market Cap | $14.34B | $12.91B |
Sector | Financials | Technology |
52-Week High | $22.68 | $117.75 |
52-Week Low | $17.45 | $82.26 |
Dividend Yield | 9.61% | 0.24% |
Enterprise Value | — | $15.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARCC trades at $19.875, down 0.53% on the day, with strong analyst support showing 24 buy ratings and a consensus price target of $19.63. The stock maintains a bullish technical signal with moving averages supporting upward momentum, though oscillators indicate some near-term pressure. Recent earnings showed Q2 2026 EPS of $0.47, slightly below expectations, while the company continues its 17-year dividend streak with consistent $0.48 quarterly payments.
The outlook remains positive with solid fundamentals including 81.77% net income margin and 6.88% ROE, though investors should monitor declining revenue trends from $1.7B in 2024 to projected $1.2B in 2026. Key risks include private credit market strain and dividend coverage tightening to 104%, while institutional confidence remains high with no sell ratings among 32 analysts covering the stock.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
